NCM
IRD

Nantahala Capital Management’s Opus Genetics IRD Stock Holding History

Nantahala Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Buy
3,061,359
+1,380,029
+82% +$6.44M 0.42% 68
2026
Q1 		$7.65M Sell
1,681,330
-3,100,000
-65% -$10.7M 0.28% 81
2025
Q4 		$9.61M Buy
4,781,330
+1,435,407
+43% +$2.91M 0.32% 73
2025
Q3 		$5.52M Hold
3,345,923
– – 0.19% 100
2025
Q2 		$3.15M Buy
3,345,923
+188,028
+6% +$174K 0.12% 111
2025
Q1 		$3.1M Buy
+3,157,895
New +$3.53M 0.12% 96

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Nantahala Capital Management's IRD Position: Q2 2026 in Review

Nantahala Capital Management increased its Opus Genetics (IRD) stake by 82% in Q2 2026, buying an estimated $6.44M and bringing the position to 3,061,359 shares worth $12.6M. The position accounts for 0.42% of the portfolio, ranked #68.

Nantahala Capital Management first reported a position in IRD in Q1 2025 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Nantahala Capital Management held 3,061,359 shares of Opus Genetics worth $12.6M as of Q2 2026.
  • Nantahala Capital Management bought 1,380,029 Opus Genetics shares in Q2 2026, an estimated $6.44M.
  • Opus Genetics made up 0.42% of Nantahala Capital Management's portfolio in Q2 2026, its #68 holding.
  • Nantahala Capital Management first reported a position in Opus Genetics in Q1 2025 and has held it in 6 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.